---
title: "Phio Pharmaceuticals tumbles 11% on INTASYL patent approvals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292806447.md"
description: "Phio Pharmaceuticals (PHIO) tumbled 11% to $0.917 after announcing patent approvals for INTASYL compound in US, Canada, Japan."
datetime: "2026-07-15T19:01:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292806447.md)
  - [en](https://longbridge.com/en/news/292806447.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292806447.md)
---

# Phio Pharmaceuticals tumbles 11% on INTASYL patent approvals

Phio Pharmaceuticals(PHIO.US) 盘中跌**10.97%**，现报**0.917 美元**。

公司 7 月 15 日宣布知识产权组合取得重大进展，INTASYL 化合物在美国、加拿大和日本获得多项许可通知及授权决定。目前全球专利组合已涵盖 54 项已授权专利，覆盖 INTASYL 化学及免疫肿瘤学靶点。首席执行官 Robert Bitterman 表示，这些进展将支持战略合作伙伴关系和商业化工作。

### Related Stocks

- [PHIO.US](https://longbridge.com/en/quote/PHIO.US.md)

## Related News & Research

- [Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894](https://longbridge.com/en/news/295525767.md)
- [Phio net loss widens to $4.14 million in Q2 FY26](https://longbridge.com/en/news/295141049.md)
- [Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026 | PHIO Stock News](https://longbridge.com/en/news/282184588.md)
- [03:07 ETHot off the Press: Recent Publications from Improved Pharma and Varda Space Industries Collaboration](https://longbridge.com/en/news/285165527.md)